Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
89.4M
-
Number of holders
-
131
-
Total 13F shares, excl. options
-
60.5M
-
Shares change
-
-1.18M
-
Total reported value, excl. options
-
$883M
-
Value change
-
-$73.5M
-
Put/Call ratio
-
0.61
-
Number of buys
-
68
-
Number of sells
-
-77
-
Price
-
$14.59
Significant Holders of Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) as of Q2 2021
176 filings reported holding TVTX - Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2021.
Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) has 131 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 60.5M shares
of 89.4M outstanding shares and own 67.72% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (5.75M shares), RA CAPITAL MANAGEMENT, L.P. (5.61M shares), BlackRock Inc. (4.99M shares), MACQUARIE GROUP LTD (3.91M shares), JANUS HENDERSON GROUP PLC (3.91M shares), VANGUARD GROUP INC (3.83M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (3.59M shares), STATE STREET CORP (3.45M shares), GOLDMAN SACHS GROUP INC (2.46M shares), and PERCEPTIVE ADVISORS LLC (1.85M shares).
This table shows the top 131 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.